Charting the Territory: End-of-Life Trajectories for Children With Complex Neurological, Metabolic, and Chromosomal

Danielle Bao1, Leanne Feichtinger2, Gail Andrews2

  • 1Department of Pediatrics, BC Children's Hospital, Vancouver, British Columbia, Canada; Department of General Medicine, The Royal Children's Hospital, Melbourne, Australia.

Insights

Children with rare life-threatening conditions experienced increased symptoms and opioid use near death. Do Not Attempt Resuscitation orders also increased, highlighting the need for better end-of-life care planning.

Area of Science:

  • Pediatric oncology
  • Palliative care
  • Rare diseases

Background:

  • Limited information exists on symptoms, illness trajectory, and end-of-life care for children with rare life-threatening conditions.
  • Care is often reactive due to a lack of understanding of these complex illnesses.

Purpose of the Study:

  • To describe patient characteristics, symptoms, medication use, resuscitation orders, and end-of-life care in a cohort of children with rare life-threatening conditions.
  • To inform more responsive and anticipatory care strategies.

Main Methods:

  • Descriptive analysis of a bereaved cohort from the Charting the Territory study (n=54 deaths).
  • Data collected via chart review, interviews, and surveys, including baseline and end-of-life information.
  • Analysis focused on 51 children with complete medical records.

Main Results:

  • Median symptoms increased from 2 at baseline to 3 at time of death.
  • Opioid use increased from 15.7% at baseline to 56.9% in the last 48 hours of life.
  • Do Not Attempt Resuscitation orders increased from 33.3% to 64.7%, with 31.4% dying in hospice.

Conclusions:

  • Increased symptom burden and changes in medical interventions near death underscore the need for better understanding of rare pediatric conditions.
  • Developing knowledge of symptoms and illness trajectory can lead to more responsive and anticipatory palliative care, easing suffering.
Abstract

Related Concept Videos

Pharmacokinetics in Pediatric Patients: Drug Metabolism01:24

Pharmacokinetics in Pediatric Patients: Drug Metabolism

In pediatric care, understanding the nuances of hepatic drug metabolism is crucial, as it significantly differs from that of adults. This divergence is primarily due to the developmental stage of drug-metabolizing enzymes, which affects how medications are processed in the body. In neonates, for instance, the activity of Phase I enzymes—critical for the initial breakdown of drugs—is markedly reduced, functioning at just 20–40% of the levels seen in adults. This reduction poses...
108
Pharmacokinetics in Pediatric Patients: Overview and Drug Absorption01:23

Pharmacokinetics in Pediatric Patients: Overview and Drug Absorption

Understanding the physiological differences in the pediatric population is crucial for effective pharmacotherapy. Neonates, infants, and children exhibit significant variations in gastric pH, gastric emptying time, intestinal transit time, and biliary function. These variations profoundly affect oral drug absorption, necessitating a nuanced approach to pediatric dosing.Neonates present with a unique physiological profile, having a gastric pH greater than 4 and faster and more irregular gastric...
145
Pharmacokinetics in Pediatric Patients: Drug Excretion01:26

Pharmacokinetics in Pediatric Patients: Drug Excretion

In pediatric medicine, understanding the renal function and drug elimination nuances is crucial for administering safe and effective treatments. Newborns, in particular, display markedly slower renal functions than adults, profoundly affecting how drugs are cleared from their bodies. This slower drug clearance requires clinicians to extend the dosing intervals for many medications to prevent drug accumulation and toxicity while ensuring therapeutic efficacy.One key area where these adjustments...
131
Inborn Errors of Metabolism01:20

Inborn Errors of Metabolism

Phenylketonuria (PKU) is a protein metabolism disorder characterized by high blood levels of the amino acid phenylalanine. This results from a mutation in the gene responsible for phenylalanine hydroxylase, an enzyme that converts phenylalanine into tyrosine. When this enzyme is deficient, phenylalanine builds up in the blood, leading to symptoms such as vomiting, rashes, seizures, growth deficiency, and severe mental retardation. An early diagnosis and a diet restricting phenylalanine intake...
604
Meiosis vs. Mitosis02:57

Meiosis vs. Mitosis

Cell division is necessary for growth and reproduction in organisms. Mitosis aids cell growth and development by dividing somatic cells. In contrast, meiosis causes the division of germ cells and plays an essential role in sexual reproduction. Due to their unique functional requirements, mitosis and meiosis differ from each other in multiple aspects.
Before the start of mitosis and meiosis I, the cell synthesizes DNA, resulting in two homologous copies of each chromosome. DNA synthesis is...
67.2K
Pharmacokinetics in Pediatric Patients: Drug Distribution01:17

Pharmacokinetics in Pediatric Patients: Drug Distribution

Drug distribution in the pediatric population exhibits unique challenges and considerations due to the physiological differences between children, particularly neonates and infants, and adults. A crucial aspect of pediatric pharmacology is understanding how these differences impact the pharmacokinetics of various drugs, necessitating age-specific dosing strategies to ensure efficacy and safety.Neonates and infants have a higher total body water content, ~75%–90% of their body weight,...
168